Legislation Would Remove Regulatory Barriers to Foster Greater Competition from
More Affordable Alternatives to High-Priced Biologic Medications





 



CSRXP APPLAUDS U.S. SENATE REINTRODUCTION OF BIPARTISAN SOLUTION TO PROMOTE
GREATER BIOSIMILAR COMPETITION IN THE PRESCRIPTION DRUG MARKET

Legislation Would Remove Regulatory Barriers to Foster Greater Competition
from More Affordable Alternatives to High-Priced Biologic Medications



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the
following statement Friday on the introduction of the “Biosimilar Red Tape
Elimination Act” (S.1954
<[link removed]>
) in the U.S. Senate.



“CSRxP commends Senators Lee (R-UT), Paul (R-KY), Hassan (D-NH) and Luján
(D-NM) for supporting greater competition in the prescription drug marketplace
with the reintroduction of the bipartisan Biosimilar Red Tape Elimination Act,”
said CSRxP executive director Lauren Aronson. “By eliminating outdated FDA
requirements, this bipartisan, market-based solution will help bring more
biosimilars to market more quickly, fostering greater competition from more
affordable alternatives to high-priced brand name drugs to help lower prices
for patients, taxpayers and the U.S. health system.”



The Biosimilar Red Tape Elimination Act would promote policies that increase
the uptake of more affordable pharmaceuticals by expediting biosimilar
substitution. CSRxP has previously supported efforts at the FDA to incentivize
outcome reporting on patients who switch from brand biologics to biosimilars in
clinical trials to educate patients and providers on the results of these
studies and programs, as well as expand Medicare and Medicaid administrative
policies that promote biosimilar uptake.



Read more about how biosimilar competition lowers out-of-pocket costs for
patientsHERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>